NASDAQ:NAKA KindlyMD (NAKA) Stock Price, News & Analysis $4.32 -0.15 (-3.36%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About KindlyMD Stock (NASDAQ:NAKA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KindlyMD alerts:Sign Up Key Stats Today's Range$4.32▼$4.6250-Day Range$4.08▼$10.5652-Week Range$4.05▼$679.20Volume259,978 shsAverage Volume454,950 shsMarket Capitalization$75.17 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingHold Company Overview Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT. Read More KindlyMD Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreNAKA MarketRank™: KindlyMD scored higher than 93% of companies evaluated by MarketBeat, and ranked 35th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingKindlyMD has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialKindlyMD has a consensus price target of $30.00, representing about 594.4% upside from its current price of $4.32.Amount of Analyst CoverageKindlyMD has only been the subject of 3 research reports in the past 90 days.Read more about KindlyMD's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for KindlyMD are expected to grow in the coming year, from ($16.80) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KindlyMD is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KindlyMD is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKindlyMD has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.50% of the float of KindlyMD has been sold short.Short Interest Ratio / Days to CoverKindlyMD has a short interest ratio ("days to cover") of 1.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in KindlyMD has recently decreased by 96.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKindlyMD does not currently pay a dividend.Dividend GrowthKindlyMD does not have a long track record of dividend growth. News and Social Media4.6 / 5News Sentiment1.43 News SentimentKindlyMD has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for KindlyMD this week, compared to 1 article on an average week.Search Interest5 people have searched for NAKA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows3 people have added KindlyMD to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $992,908.00 in company stock, which represents 1.3209% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, KindlyMD insiders have bought more of their company's stock than they have sold. Specifically, they have bought $992,908.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders24.49% of the stock of KindlyMD is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsKindlyMD has minimal institutional ownership at this time.Read more about KindlyMD's insider trading history. Receive NAKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KindlyMD and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAKA Stock News HeadlinesKindlyMD (NASDAQ:NAKA) CEO David Bailey Acquires 31,500 SharesMay 29, 2026 | insidertrades.comNakamoto Chairman and CEO David Bailey Purchases Additional Shares of Common StockMay 28, 2026 | businesswire.comTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.June 12 at 1:00 AM | Behind the Markets (Ad)Nakamoto Announces Expansion of Board of DirectorsMay 22, 2026 | businesswire.comBattered stock attempts reverse split to avoid Nasdaq delistingMay 20, 2026 | thestreet.comFollowing Stockholder Approval, Nakamoto Announces 1-for-40 Reverse Stock Split to be Effective on May 22, 2026May 20, 2026 | businesswire.comBitcoin Magazine Announces BM TV: A Daily Markets Broadcast Network for Bitcoin's Institutional EraApril 27, 2026 | businesswire.comUTXO Management Announces UTXO Preferred Income Strategies LP, a Dual-Class Structured Income Fund Targeting Digital Credit Preferred SecuritiesApril 27, 2026 | businesswire.comSee More Headlines NAKA Stock Analysis - Frequently Asked Questions How have NAKA shares performed this year? KindlyMD's stock was trading at $14.0440 at the start of the year. Since then, NAKA stock has decreased by 69.2% and is now trading at $4.32. How were KindlyMD's earnings last quarter? KindlyMD, Inc. (NASDAQ:NAKA) issued its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.38) earnings per share (EPS) for the quarter. The business earned $2.68 million during the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative trailing twelve-month return on equity of 81.32%. When did KindlyMD's stock split? KindlyMD's stock reverse split before market open on Friday, May 22nd 2026.The 1-40 reverse split was announced on Wednesday, May 20th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 21st 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of KindlyMD? Shares of NAKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/13/2026Today6/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 NAKA's financial health is in the Red zone, according to TradeSmith. NAKA has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:NAKA Previous SymbolNASDAQ:NAKA CIK1946573 WebN/A Phone(385) 388-8220FaxN/AEmployeesN/AYear Founded2019Price Target and Rating Average Price Target for KindlyMD$30.00 High Price Target$40.00 Low Price Target$20.00 Potential Upside/Downside+594.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($43.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.23 million Net Margins-7,397.12% Pretax Margin-7,397.12% Return on Equity-81.32% Return on Assets-54.17% Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual Sales$1.82 million Price / Sales41.30 Cash FlowN/A Price / Cash FlowN/A Book Value$46.97 per share Price / Book0.09Miscellaneous Outstanding Shares17,400,000Free Float13,140,000Market Cap$75.17 million OptionableN/A Beta15.84 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:NAKA) was last updated on 6/12/2026 by MarketBeat.com Staff. From Our PartnersDo NOT Buy SpaceX – Do This InsteadSpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...Stansberry Research | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredWrite down this ticker today…Hedge fund legend Larry Benedict - who beat the S&P 500 by 18 times in 2025 and made clients $95 million durin...Brownstone Research | SponsoredAn Elon Musk Fan's Warning About SPCXJon Najarian called Tesla in 2014 when legacy automakers dismissed it. Now he's warning investors to skip SPCX...Banyan Hill Publishing | SponsoredSpaceX Opens Up 11% — Here’s What You Need to KnowSpaceX - ticker SPCX - just completed the biggest IPO in American history, raising $75 billion at a $1.8 trill...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KindlyMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KindlyMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.